4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Terminated
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to estimate the modulation of intermediate biological
endpoints of the combination of 4-HPR and SCH66336, a farnesyl transferase inhibitor (FTI),
across 4 randomly assigned dose levels in patients with locally advanced or recurrent head
and neck cancer. We will also assess the activity, safety, tolerability and side effects of
4-HPR/SCH66336 and hope to establish a phase II regimen.